Barinthus Biotherapeutics plc (FRA:2AB)

Barinthus Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	59.3	70.46	110.66	142.09	194.39	214.05
Cash & Short-Term Investments	59.3	70.46	110.66	142.09	194.39	214.05
Cash Growth	-31.26%	-36.33%	-22.12%	-26.90%	-9.19%	394.74%
Accounts Receivable	-	-	-	-	5.85	0.02
Other Receivables	1.63	1.31	7.14	7.94	6.31	6.93
Receivables	1.63	1.31	7.14	7.94	12.16	6.95
Prepaid Expenses	1.87	4.52	5.86	5.4	5.89	4.61
Restricted Cash	0.34	1.4	1.74	-	-	-
Other Current Assets	0.15	0.12	0.34	1.47	0.61	1.15
Total Current Assets	63.27	77.79	125.74	156.91	213.04	226.77
Property, Plant & Equipment	4.66	5.16	11.76	19.4	15.71	9.09
Goodwill	-	-	-	12.21	12.21	12.63
Other Intangible Assets	13.05	14.29	21.95	25.11	28.27	31.43
Other Long-Term Assets	0.92	0.93	0.88	0.88	0.98	0.8
Total Assets	81.89	98.17	160.33	214.51	270.21	280.72

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	0.54	0.35	2.47	1.6	3.75	2.42
Accrued Expenses	8.83	6.25	9.53	9.21	8.06	7.88
Short-Term Debt	-	-	-	-	-	0.16
Current Portion of Leases	1.72	2.02	1.92	1.79	0.43	0.52
Current Unearned Revenue	0.34	1.4	1.74	-	-	0.18
Total Current Liabilities	11.42	10.02	15.66	12.6	12.24	11.16
Long-Term Leases	8.57	9.26	10.09	11.19	8.34	6.54
Long-Term Deferred Tax Liabilities	0.22	0.25	0.44	0.57	3.75	8.08
Other Long-Term Liabilities	4.55	4.35	4.01	3.15	2.68	2.37
Total Liabilities	24.76	23.88	30.19	27.51	27	28.15

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	394.93	393.94	393.47	386.6	379.5	369.1
Retained Earnings	-320.21	-304.09	-237.66	-176.59	-103.24	-108.59
Comprehensive Income & Other	-17.65	-15.65	-25.78	-23.23	-33.37	-8.39
Total Common Equity	57.07	74.21	130.03	186.78	242.9	252.13
Minority Interest	0.06	0.08	0.11	0.21	0.31	0.44
Shareholders' Equity	57.13	74.29	130.14	187	243.2	252.56
Total Liabilities & Equity	81.89	98.17	160.33	214.51	270.21	280.72

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	10.3	11.28	12.01	12.98	8.77	7.22
Net Cash (Debt)	49	59.18	98.66	129.11	185.61	206.83
Net Cash Growth	-34.02%	-40.02%	-23.59%	-30.44%	-10.26%	-
Net Cash Per Share	1.20	1.46	2.51	3.36	4.86	7.99
Filing Date Shares Outstanding	40.85	40.85	40.34	38.92	38.34	37.19
Total Common Shares Outstanding	40.85	40.85	40.23	38.64	37.68	37.19
Working Capital	51.85	67.77	110.09	144.31	200.8	215.61
Book Value Per Share	1.40	1.82	3.23	4.83	6.45	6.78
Tangible Book Value	44.03	59.92	108.08	149.47	202.42	208.07
Tangible Book Value Per Share	1.08	1.47	2.69	3.87	5.37	5.59
Machinery	-	2.2	7.51	6.84	5.35	2.09
Leasehold Improvements	-	8.91	9.28	8.67	3.93	0.63

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 23, 2026

Data Sources Report a data error